Mecbotamab vedotin  (Synonyms: BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC)

Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Vedotin (HY-15162)^[1].

AXL; BA301 γ1^[1]

Mecbotamab vedotin (0.1-10000 ng/mL) efficiently binds to AXL at pH 6.0 in DU145 cells (EC₅₀ = 16 ng/mL), LCLC-103H cells (EC₅₀ = 37 ng/mL), 293-huAXL (EC₅₀ = 56 ng/mL) and 293-cynoAXL (EC₅₀ = 20 ng/mL)^[1].
Mecbotamab vedotin (0.01-10000 ng/mL, 3 days) exhibits significant cytotoxicity at pH 6.0 in DU145 cells (IC₅₀ = 1466 ng/mL) and LCLC-103H cells (IC₅₀ = 474 ng/mL) but is non-toxic to 293-F cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mecbotamab vedotin (1-6 mg/kg, i.v., once every 4 days, for 6 times) significantly inhibits tumor growth in female NOD/SCID mice bearing LCLC-103H tumors^[1].
Mecbotamab vedotin (1-10 mg/kg, i.v., once every 4 days, for 4 times) significantly inhibits tumor growth in female NOD/SCID mice bearing MIA PaCa-2 tumors^[1].
Mecbotamab vedotin (6-15 mg/kg, i.v., once every 4 days, for 6 times) significantly delayed tumor growth in male BALB/c nude mice bearing DU145 tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2460400-64-8

Liquid

Colorless to light yellow

[Mecbotamab vedotin]

Shipping with dry ice.

-80°C, protect from light

• [1]. Chang HW, et al. Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate. Antib Ther. 2025 Apr 10;8(2):145-156.  [Content Brief]